EP3124609A1 — Therapeutics oligonucleotides
Assigned to IFOM Fondazione Istituto FIRC di Oncologia Molecolare · Expires 2017-02-01 · 9y expired
What this patent protects
The present invention relates to oligonucleotides that hybridize to small RNAs. In particular the oligonucleotide comprises one of the following sequences: (TTAGGG) SEQ ID No. 1, (TAGGGT) SEQ ID No. 2, (AGGGTT) SEQ ID No. 3, (GGGTTA) SEQ ID No. 4, (GGTTAG) SEQ ID No. 5 or (GTTAGG…
USPTO Abstract
The present invention relates to oligonucleotides that hybridize to small RNAs. In particular the oligonucleotide comprises one of the following sequences: (TTAGGG) SEQ ID No. 1, (TAGGGT) SEQ ID No. 2, (AGGGTT) SEQ ID No. 3, (GGGTTA) SEQ ID No. 4, (GGTTAG) SEQ ID No. 5 or (GTTAGG) SEQ ID No. 6 or a complementary sequence thereof or a fragment or a variant thereof for use in the treatment and/or prevention of a disease characterized by alternative lengthening of telomeres or a telomere syndrome and relative pharmaceutical compositions.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.